The adsorption of allergoids and 3-O-desacyl-4′-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy  by Bell, A.J. et al.
Journal of Inorganic Biochemistry 152 (2015) 147–153
Contents lists available at ScienceDirect
Journal of Inorganic Biochemistry
j ourna l homepage: www.e lsev ie r .com/ locate / j inorgb ioThe adsorption of allergoids and 3-O-desacyl-4′-monophosphoryl lipid A
(MPL®) to microcrystalline tyrosine (MCT) in formulations for use in
allergy immunotherapyA.J. Bell ⁎, M.D. Heath, S.J. Hewings, M.A. Skinner
Allergy Therapeutics, Plc, Dominion Way, Worthing BN14 8SA, United KingdomAbbreviations:MPL®, monophosphoryl lipid A; MCT, m
World Health Organisation; EMA, European Medicines Ag
tyrosine adsorbed; C–H⋯π, carbon hydrogen delocalised
IgE, immunoglobulin E; GC, gas chromatography; Th2, su
immune response; TLR4, toll-like receptor four; IgG, immu
loid differential protein 2:toll-like receptor four complex
goodmanufacturing practice;WFI, water for injections; UK
Ph. Eur, European Pharmacopeia; RPM, revolutions per m
force; FID, ﬂame ionisation detector; PSI, pounds per squ
immunosorbent assay; DPBS, Dulbecco's phosphate buffer
bumin; QAU, quality assurance units; MPL-AF, monophos
tion; SD, standard deviation; %RSD, percentage relative st
aromatic electrons; Plc, public limited company.
⁎ Corresponding author.
http://dx.doi.org/10.1016/j.jinorgbio.2015.08.007
0162-0134/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 15 April 2015
Received in revised form 29 July 2015
Accepted 5 August 2015
Available online 15 August 2015
Keywords:
Adjuvant adsorption
Allergoid
Monophosphoryl lipid A
Microcrystalline tyrosine
Modiﬁed allergen tyrosine adsorbed
C–H⋯π interactionsInfectious disease vaccine potency is affected by antigen adjuvant adsorption. WHO and EMA guidelines recom-
mend limits and experimental monitoring of adsorption in vaccines and allergy immunotherapies. Adsorbed
allergoids and MPL® in MATA-MPL allergy immunotherapy formulations effectively treat IgE mitigated allergy.
Understanding vaccine antigen adjuvant adsorption allows optimisation of potency and should be seen as
good practice; however current understanding is seldom applied to allergy immunotherapies.
The allergoid andMPL® adsorption toMCT inMATA-MPL allergy immunotherapy formulations was experimen-
tal determination using speciﬁc allergen IgE allerginicity and MPL® content methods. Binding forces between
MPL® and MCT were investigated by competition binding experiments.
MATA-MPL samples with different allergoids gave results within 100–104% of the theoretical 50 μg/mL MPL®
content. Unmodiﬁed drug substance samples showed signiﬁcant desirable IgE antigenicity, 1040–170 QAU/mL.
MATA-MPL supernatant samples with different allergoids gave results of ≤2 μg/mL MPL® and ≤0.1–1.4
QAU/mL IgE antigenicity, demonstrating approximately ≥96 & 99% adsorption respectively. Allergoid and
MPL® adsorption in different MATA-MPL allergy immunotherapy formulations is consistent and meets
guideline recommendations. MCT formulations treated to disrupt electrostatic, hydrophobic and ligand
exchange interactions, gave an MPL® content of ≤2 μg/mL in supernatant samples. MCT formulations treated
to disrupt aromatic interactions, gave an MPL® content of 73–92 μg/mL in supernatant samples. MPL® adsorption
to L-tyrosine in MCT formulations is based on interactions between the 2-deoxy-2-aminoglucose backbone on
MPL® and aromatic ring of L-tyrosine in MCT, such as C–H⋯π interaction. MCT could be an alternative adjuvant
depot for some infectious disease antigens.
© 2015 The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Infectious disease vaccines and allergy immunotherapy formula-
tions often include an adjuvant to enhance efﬁcacy, with aluminium
salts being the most commonly used adjuvant. The strength and typeicrocrystalline tyrosine; WHO,
ency; MATA, modiﬁed allergen
aromatic electron interaction;
bset of innate allergen speciﬁc
noglobulin G;MD2:TLR4, mye-
; C–H, carbon hydrogen; GMP,
, United Kingdom; Ltd, limited;
inute; RCF, relative centrifugal
are inch; ELISA, enzyme-linked
ed saline; BSA, bovine serumal-
phoryl lipid A aqueous formula-
andard deviation; π, delocalised
. All rights reserved. This is an open aof adsorption in some infectious disease vaccines, such as anthrax, diph-
theria and hepatitis B can affect antigen stability and potency, and
therefore should be optimised [1–8]. The World Health Organisation
(WHO) recommends adsorption of at least 80% of tetanus and diphthe-
ria toxoid antigen to aluminium adjuvants in vaccines [9].
The WHO and European Medicines Agency (EMA) recommend the
degree of antigen to aluminium adjuvant adsorption be characterised
on manufacture and over the shelf life of the vaccine [10,11], the pres-
ence of human immunoglobulin E (IgE) binding components in the su-
pernatant of adsorbed allergen products should be determined [12] and
the content and degree of adsorption of MPL® in Hepatitis B vaccines
should be determined using a suitablemethod e.g., gas chromatography
(GC) [13]. The interactions of antigen and adjuvant in infectious disease
vaccines have been investigated and documented therefore should be
considered good practice in allergy immunotherapy where such under-
standing is too often not applied [14–16].
The strongest binding force between antigens and aluminium adju-
vants is ligand exchange, between the available hydroxyl surface groupsccess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tigen [17,18].
Formulation conditions such as pH, ionic strength, buffer type and
other excipients should be optimised in relation to antigen charge states
or isoelectric points, to provide appropriate vaccine adsorption, stability
and potency [19–22]. Commonly aluminium adjuvants are formulated
in excess with the antigen or allergen, to ensure sufﬁcient adsorption
and increased efﬁcacy.
However the inﬂammatory response produced by aluminium adju-
vants may not be aligned with the Th2 hypothesis in allergy treatment
[23–26].
Safety concerns regarding the accumulation of aluminium following
multiple sub-cutaneous allergy immunotherapy injections [27–29] and
the need for more appropriate adjuvants in allergy immunotherapy
formulations, has led to the use of toll-like receptor (TLR4) agonist
monophosphoryl lipid A (MPL®) [30–33]. Glutaraldehydemodiﬁed aller-
genic extracts (allergoids) from grass, tree and ragweed pollens have re-
duced IgE reactivity, but maintain IgG reactivity [34] and are readily
adsorbed to the microcrystalline tyrosine (MCT) in modiﬁed allergen ty-
rosine adsorbed (MATA) formulations. Clinical studies have shown that
the addition ofMPL® toMATA allergy immunotherapy formulations pro-
vides a more effective treatment for IgE mediated allergy [35–40]. The
contribution of electrostatic, hydrophobic and ligand exchange binding
forces between antigens and aluminium adjuvants has been investigated
by the addition of ethylene glycol and ionic species [41,42]. The nature of
allergoid and MPL® association in commercially available MATA-MPL al-
lergy immunotherapy formulations has not previously been investigated
and compared to guideline recommendations.
The structure of MPL® consists of a B′1 -N 6-linked disaccharide
backbone of 2-deoxy-2-aminoglucose phosphorylated at the 4′ posi-
tion, which differs in the length of fatty acid substitutions at the 2, 2′
and 3′ positions [43], see Fig. 2. The distinct hydrophilic 2-deoxy-2-
aminoglucose phosphorylated and hydrophobic fatty acid chain regions
of MPL® lead lipid A motifs to form aggregates in aqueous solutions
[44,45]. The formation and shape of these aggregates is essential to
MD2:TLR4 complex dimerization and species speciﬁc pro-inﬂammatory
cytokine pathway activation [46,47]. Carbohydrate protein interactions
have been shown to depend signiﬁcantly on C–H⋯π attraction between
the saccharide structures in carbohydrates and aromatic amino acids in
proteins including L-tyrosine [48–50].
Studies have shown that saccharide structureswith three ormore up-
ward facing C–H groups like the 2-deoxy-2-aminoglucose in the MPL®
backbone can interact with aromatic centres through C–H⋯π attraction
and this is the predominant associated seen within carbohydrate protein
stacked structures [51]. Commercially available MATA-MPL allergy im-
munotherapy formulations were tested for adsorption of MPL® and
allergoid, for comparison against guideline recommendations. Speciﬁc
MPL® content and allergen IgE reactivity methods used are presented.
The nature of the adsorption ofMPL® toMCT is investigated and the pos-
sible mechanism of adsorption between MPL® and MCT is described in
the context of experimental results seen.
2. Experimental
2.1. Materials
2.1.1. 100 μg/mL MPL® aqueous formulation
Commercially available good manufacturing practice (GMP) grade
(Avanti Polar Lipids Inc.) triethylamine salt ofMPL® (100mg) and surfac-
tant dipalmitoyl phosphatidyl choline (11 mg) were dispersed in 1 L of
water for injections (WFI) to give concentrations of 100 μg/mL and
11 μg/mL, respectively. Microﬂuidisation with an Avestin Emulsiﬂex C/
55 at 130 revolutions per minute (RPM) for 30 min was used to give a
homogeneous aqueous formulation, before sterile ﬁltration with a
0.22 μm ﬁlter (Sterile Millipak®-200). This solution was used as a
standard in the Gas Chromatography (GC) MPL® content assay [52].2.1.2. MATA-MPL immunotherapy formulations
Commercially available MATA-MPL immunotherapy formulations
for grass, birch, tree, grass & tree, grass & birch and grass & mugwort
were all sourced from Allergy Therapeutics (UK) Ltd and contain
2% w/v tyrosine, 0.5% w/v phenol, 50 μg/mL MPL® and a clinically
standardised speciﬁc allergoid amount. TheseMATA-MPL immunother-
apy formulations were used to investigate MPL® and allergoid adsorp-
tion. MPL® content was tested in both formulation and supernatant,
while allergen speciﬁc IgE reactivity was tested for in the supernatant.
2.1.3. Unmodiﬁed drug substance
Unmodiﬁed drug substance solutions were sourced from Allergy
Therapeutics (UK) Ltd and comprised of 5% w/v grass, tree, birch
and mugwort pollen species aqueous extracts in Evans solution
(pH 7). The Evans solution consisted of commercially available (Fisher
Scientiﬁc Ph. Eur.) anhydrous salts of disodium hydrogen phosphate
(0.121% w/v), potassium dihydrogen phosphate (0.03% w/v), sodium
chloride (0.417% w/v) and phenol (0.60% w/v) in WFI. Evans solution
and aqueous pollen extracts were sterile ﬁltered to 0.22 μm (Sterile
Millipak®-200). Manufacture and source materials comply with EMA
and European Pharmacopeia (Ph. Eur.) guidelines [12,53]. These
unmodiﬁed drug substance solutions were used to conﬁrm allergen
speciﬁc IgE reactivity for comparison toMATA-MPL supernatant results.
2.1.4. MCT test formulation (4% w/v L-tyrosine and 0.5% w/v phenol)
Commercially available (Fisher Scientiﬁc Ph.Eur.) sodium hydroxide
pellets (152 g)were dissolved volumetrically in 1 L ofWFI giving a 3.8M
sodium hydroxide solution. Commercially available (Sigma. Ph. Eur.)
37% (36.46 g/mol) hydrochloric acid (138.55 g)was diluted volumetrical-
ly in 1 L of WFI giving a 3.8 M hydrochloric acid solution. Commercially
available (Ph. Eur.) L-tyrosine (240 g) was dissolved volumetrically in
1 L of 3.8 M hydrochloric acid, to give a 24% w/v L-tyrosine in 3.8 M
hydrochloric acid solution.
Sodium hydroxide and hydrochloric acid solutions were sterile ﬁl-
tered to 0.22 μm (Sterile Millipak®-200). MCT was precipitated by
adding together equal volumes of 3.8 M sodium hydroxide and 24%
w/v L-tyrosine in 3.8 M hydrochloric acid solution, using a Silverson
homogeniser at 6000 RPM and equal ﬂow rates of 50 mL/min using
Flexicon peristaltic pumps. The resulting 12% w/v L-tyrosine sus-
pension was then diluted 1:4 with a sterile ﬁltered to 0.22 μm
(Sterile Millipak®-200), Evans solution (pH 7). TheMCT test formulation
without MPL® was used in MPL® competition binding experiments.
2.1.5. Grass MATA test formulation
Grass MATA formulation without MPL® was sourced from Allergy
Therapeutics (UK) Ltd and comprises of a 13 grass species drug sub-
stance Evans solution (pH 7) aqueous extract, modiﬁed with aqueous
0.05% v/v glutaraldehyde (Fisher Scientiﬁc Ph. Eur.). Modiﬁed drug sub-
stance aqueous extracts are diaﬁltered usingMillipore Pelican 2 ultraﬁl-
tration cassettes, to remove low molecular weight moieties. The
allergoids in the aqueous extract are adsorbed to MCT on precipitation
and then diluted with MCT to the required clinical strength. Manufac-
ture and source materials comply with EMA and Ph. Eur. guidelines
[12,53]. The Grass MATA test formulation without MPL® was used in
MPL® competition binding experiments.
2.2. Methods
All chemicals and reagents used in methods are commercially avail-
able analytical grade unless otherwise stated.
2.2.1. MPL content assay
Samples were prepared and tested in duplicate. Test formulations
and MATA-MPL samples were mixed for 10 min on a roller mixer at
35 RPM. Following mixing 1 mL aliquots were taken for MPL® content
testing of the formulation. Test formulations and MATA-MPL samples
Fig. 1. Calibration curve and chromatogram from GC MP®L content assay.
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tant. Following centrifugation 1 mL aliquots of the supernatant were
taken for MPL® content testing. Calibration standards were prepared
by taking 30, 150, 250, 500, 1000, and 1500 μL aliquots of the
100 μg/mL MPL® aqueous formulation. Test formulations, MATA-MPL,
supernatant and calibration standard samples were all placed in 6 mL
Duran culture tubes. 1000 μL of 66.7 μg/mL pentadecanoic acid in aque-
ous 0.05 g/mL sodium hydroxide solution was added to each test
sample.
Test samples were then heated for 60 min at 100 °C and then
allowed to cool.
1500 μL of 25% w/v hydrochloric acid in 50% w/v methanol solution
was then added to each test sample. Test samples were then heated for
30min at 80 °C and then allowed to cool. Pentadecanoic acid was intro-
duced as an internal standard in the sodium hydroxide solution. 1 mL of
aqueous 37.5 g/L sodium chloride solution was added to each test sam-
ple, followed by 1 mL of hexane.
The Duran culture tube was vortex mixed for 20 s after each addi-
tion. 800 μL of the upper hexane layer was taken from each sample
Duran culture tube and transferred to a separate 4 mL screw cap vial
containing 550 mg of sodium sulphate.
50 μL of triﬂuoroacetic anhydride was then added to each test sam-
ple, before vortexmixing for 20 s. Test sample vialswere then heated for
1 h at 60 °C and then allowed to cool. 1 mL of aqueous 37.5 g/L sodium
chloride solution was added to each test sample.
300 μL of the hexane layer from each test sample was then trans-
ferred to a GC auto-sampler vial for injection. Test samples were run
on an Agilent 7890 GC with ﬂame ionisation detector (FID) using a
capillary (HP-1), 30 m × 0.32 × 0.25 μm (5%-Phenyl-95% Methyl-
polysiloxane) column. The following oven temperature gradient
was used, initial temperature 50 °C hold for 2.5 min, increasing at
4.8 °C per minute to a ﬁnal temperature of 250 °C and post run
320 °C hold for 5min. The following injector settings were used, tem-
perature 250 °C, splitless injection, ﬂow rate 1 mL/min (constant
pressure 5.35 PSI), purge ﬂow 50.9 mL/min and purge time 1.5 min.
Injection volume 2.0 μL, injection solvent washes: 2 and sample
pumps: 6. The following FID settings were used, temperature350 °C, hydrogen ﬂow 40 mL/min, air ﬂow 450 mL/min, make up
gas helium, constant ﬂow plus make up gas 18 mL/min. The MCT in
MATA-MPL samples were dissolved upon the acid/alkali addition en-
suring maximum recovery. Triﬂuoroacetic anhydride was used to
form fatty acid methyl esters in the methanolic solutions.
Hexane was used to isolate the free fatty acids from the aqueous
phase via liquid–liquid extraction. Following the acid/alkali addition
and heating of the samples at 100 °C for 60 min, dodecanoic acid,
tetradecanoic acid, 3-hydroxy tetradecanoic acid and hexadecanoic
acid free fatty acids from MPL® were dissociated from the intact mole-
cule in all samples. The resulting calibration curve and GC chromato-
gram can be seen in Fig. 1. The ratio between the total peak area of
fatty acid methyl esters from MPL® and peak area of internal standard
can be related via a calibration curve to theMPL® content of the sample
in μg/mL [52].2.2.2. IgE ELISA assay
Potency enzyme-linked immunosorbent assay (ELISA) [54] was
used to measure the IgE reactivity in MATA-MPL supernatant and un-
modiﬁed drug substance samples. Allergen speciﬁc IgE reactivity was
determined by using a competition ELISA. Polystyrene microtitre plates
(Costar 3590) were incubated at 2–8 °C overnight with a standardised
allergen reference diluted 1:4 with Dulbecco's phosphate buffered
saline (DPBS, Sigma).
The plates were washed with DPBS + 0.1% Tween 20 (Sigma)
and blocked with 1% BSA (Sigma) in coating buffer. After washing,
plates were loaded with samples followed by human anti-allergen
IgE sera (pooled from a number of atopic patients) and incubated
for 2 h at 37 °C. The plates were washed and incubated with goat
anti-human IgE horseradish peroxidase, then developed with 3,3′,5,5′-
tetramethylbenzidine peroxidase substrate (KPL) for 30 min at room
temperature. The reaction was stopped with 1.0 M Orthophosphoric
acid (Fisher Scientiﬁc) and the individual plate well absorbance read
at 450 nm using a Perkin Elmer Envision plate reader. The mean absor-
bance for each sample well was calculated and IgE reactivity compared
against a clinically established reference (QAU/mL).
Table 4
MPL® adsorption time studies with MCT and Grass MATA test formulations.
Table 3
MPL® MCT and Grass MATA test formulation adsorption.
Test formulation MPL® in test formulation
Mean SD %RSD
MCT ≤2 μg/mL 0.03 1.50
MCT + MPL® (80–120 μg/mL) 102 μg/mL 0.03 0.03
Grass MATA ≤2 μg/mL 0.14 8.50
Grass MATA + MPL® (80–120 μg/mL) 112 μg/mL 0.14 0.13
MPL® in supernatant
Mean SD %RSD
MCT ≤2 μg/mL 0.03 1.50
MCT + MPL® (80–120 μg/mL) ≤2 μg/mL 0.03 1.50
Grass MATA ≤2 μg/mL 0.14 7.00
Grass MATA + MPL® (80–120 μg/mL) ≤2 μg/mL 0.14 7.00
SD= standard deviation, %RSD= percentage standard deviation.
Table 1
MPL® content of MATA-MPL allergy immunotherapy formulations and supernatant
samples.
Allergoid MATA-MPL
formulation
Formulation
Mean MPL®
content
Supernatant
Mean MPL®
content
MPL® adsorbed
to MATA complex
Grass 51 μg/mL ≤2 μg/mL 96.1%
Tree 50 μg/mL ≤2 μg/mL 96.0%
Birch 50 μg/mL ≤2 μg/mL 96.0%
Grass/tree 51 μg/mL ≤2 μg/mL 96.1%
Grass/birch 51 μg/mL ≤2 μg/mL 96.1%
Grass/mugwort 52 μg/mL ≤2 μg/mL 96.2%
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1 mL of 1 mg/mL MPL-AF (GlaxoSmithKline) was added to 9 mL of
MCT or Grass MATA test formulation, to prepare test formulations con-
taining 100 μg/mL. After roller mixing for 10min at 35 RPM and storage
at 2–8 °C for 24 h, the MPL® content of test formulations and their su-
pernatants was determined by GC. Samples were prepared and tested
in duplicate.
2.2.4. MPL® adsorption time studies
0.5mL of 1mg/mLMPL-AF (GlaxoSmithKline) was added to 9mL of
MCT or Grass MATA test formulation, to prepare test formulations con-
taining 50 μg/mL. After rollermixing for 10, 30, 60 and 90min at 35 RPM
the MPL® content of test formulations and their supernatants was de-
termined by GC. Samples were prepared and tested in duplicate.
2.2.5. MPL® competition binding experiments
1 mL of 1 mg/mL MPL-AF (GlaxoSmithKline) was added to 9 mL of
MCT or Grass MATA test formulation, to prepare test formulations
containing 100 μg/mL. After roller mixing for 10 min at 35 RPM, the
MPL® content of both test formulations and their supernatants was
determined by GC.
5 mL of ethylene glycol, an ionic aqueous solution containing
2.4% w/v sodium chloride, 0.5% w/v phosphate 1.6% w/v phenol
and 8 mg/mL aqueous naphthalene solution were separately mixed
with 5 mL MCT or Grass MATA test formulations. Samples were roller
mixed for 30 min 35 RPM and stored at 2–8 °C for 12 h before MPL®
content was determined for both test formulations and their superna-
tants by GC.
3. Results and discussion
MPL® content results for all six MATA-MPL allergy immunotherapy
formulations were between 50–52 μg/mL. MPL® content results for all
six supernatant MATA-MPL formulation samples were ≤2 μg/mL, the
validated limit of detection of the GC MPL® content assay. The results
seen in Table 1 demonstrate that approximately ≥96% of the MPL® in
the MATA-MPL allergy immunotherapy formulations tested wasTable 2
IgE reactivity of MATA-MPL allergy immunotherapy formulations and supernatant
samples.
Allergoid
MATA-MPL
formulation
IgE in unmodiﬁed
drug substance
IgE in
MATA-MPL
supernatant
Allergoid adsorbed
in MATA complex
Grass 177 QAU/mL ≤0.1 QAU/mL ≤99%
Tree 163 QAU/mL ≤1.0 QAU/mL ≤99%
Birch 1040 QAU/mL ≤1.4 QAU/mL ≤99%
Grass/tree 170 QAU/mL ≤1.0 QAU/mL ≤99%
Grass/birch 609 QAU/mL ≤1.0 QAU/mL ≤99%
Grass/mugwort 251 QAU/mL ≤1.0 QAU/mL ≤99%
The MATA-MPL allergy immunotherapy formulations tested sufﬁciently control pH, ionic
strength, buffer type and other excipients to give consistent allergoid and MPL®
adsorption.absorbed to the suspended MCT in the formulation, irrespective of the
allergoid type in the MATA-MPL formulation. These results meet WHO
recommendations of at least 80% adsorption in tetanus diphtheria tox-
oid infectious disease aluminium adjuvant vaccines.
Signiﬁcant amounts of speciﬁc allergen IgE reactivity, 163–1040
QAU/mL was seen in the MATA-MPL allergy immunotherapy formula-
tions unmodiﬁed drug substances. However only low residual amounts
of speciﬁc allergen IgE reactivity ≤0.1–1.4 QAU/mL was seen for all six
MATA-MPL allergy immunotherapy formulation supernatant samples.
The results seen in Table 2 indicate that approximately ≤99% of allergoid
is absorbed to the suspended MCT, irrespective of the allergoid type in
the MATA-MPL formulation. These results meet WHO recommenda-
tions for antigen adsorption in tetanus and diphtheria toxoid infectious
disease vaccines of at least 80%.
MCT and Grass MATA test formulations without MPL®, showed no
trace of MPL® in both formulation and supernatant samples when test-
ed after preparation and storage. MCT and Grass MATA test formula-
tions with MPL® added showed MPL® in formulation samples when
tested after preparation and storage. MCT and Grass MATA test formu-
lations with MPL® added showed no MPL® in supernatant samples
when tested after preparation and storage. The results seen in Table 3
demonstrate the absence of MPL® in MCT and Grass MATA test formu-
lations and that MPL® on addition to the test formulations adsorbs
within 24 h of preparation.
MCT and Grass MATA test formulations with MPL® added showed
MPL® in formulation samples when tested after only 10minutemixing.
MCT and Grass MATA test formulations with MPL® added showed no
MPL® in supernatant sampleswhen tested after only 10minutemixing.
The results seen in Table 4 demonstrate that theMPL®adsorbed to both
MCT and Grass MATA test formulations within 10 min of mixing.Mixing time MPL® in MCT test formulation MPL® in MCT supernatant
Minutes Mean SD %RSD Mean SD %RSD
10 52 μg/mL 0.03 0.06 ≤2 μg/mL 0.10 5.00
30 50 μg/mL 0.05 0.10 ≤2 μg/mL 0.12 6.00
60 51 μg/mL 0.06 0.12 ≤2 μg/mL 0.15 7.50
90 50 μg/mL 0.08 0.16 ≤2 μg/mL 0.18 9.00
Mixing time MPL® in Grass MATA test
formulation
MPL® in Grass MATA
supernatant
Minutes Mean SD %RSD Mean SD %RSD
10 50 μg/mL 0.04 0.08 ≤2 μg/mL 0.11 5.50
30 49 μg/mL 0.02 0.04 ≤2 μg/mL 0.12 6.00
60 50 μg/mL 0.04 0.08 ≤2 μg/mL 0.10 5.00
90 51 μg/mL 0.06 0.12 ≤2 μg/mL 0.14 0.70
SD= standard deviation, %RSD= percentage standard deviation.
Table 6
Overview of MPL® content of MCT and Grass MATA formulations, containing 100 μg/mL
MPL, on addition of an aqueous naphthalene solution at a 1:1 v/v ratio.
MPL® test formulation MPL® in formulation MPL® in supernatant
Grass MATA + naphthalene 27 μg/mL 73 μg/mL
MCT + naphthalene 8 μg/mL 92 μg/mL
Table 5
Overview of MPL® content of MCT and Grass MATA formulations, containing 100 μg/mL
MPL®, on addition of ethylene glycol and an ionic aqueous solution at a 1:1 v/v ratio.
MPL® test formulation MPL® in formulation MPL® in supernatant
Grass MATA + ethylene glycol 98 μg/mL ≤2 μg/mL
MCT + ethylene glycol 101 μg/mL ≤2 μg/mL
Grass MATA + ionic solution 99 μg/mL ≤2 μg/mL
MCT + ionic solution 102 μg/mL ≤2 μg/mL
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after the addition of ethylene glycol at a 1:1 v/v ratio were 98 and
101 μg/mL MPL® respectively. MPL® content results for supernatant
samples of Grass MATA and MCT formulations on addition of ethylene
glycol at a 1:1 v/v ratio were both ≤2 μg/mL MPL®, see Table 5 for an
overview of results and Supplementary ﬁle 2 for additional data.
MPL® content results for both Grass MATA and MCT formulations
after the addition of an ionic aqueous solution at a 1:1 v/v ratio were
99 and 102 μg/mL MPL® respectively. MPL® content results for super-
natants samples of Grass MATA and MCT formulations on addition of
an ionic aqueous solution at a 1:1 v/v ratio were both ≤2 μg/mL MPL®,
see Table 5 an overview of results at a 1:1 v/v ratio and Supplementary
ﬁle 3 for additional data.
The addition of ethylene glycol or ionic solution at a 1:1 v/v ratio [41]
did not inhibit the adsorption of MPL® in both MCT and Grass MATA
test formulations.
However greater v/v ratios do inhibit the adsorption ofMPL® in both
MCT and Grass MATA test formulations, see Supplementary ﬁles 1 & 2
for additional data. Results would therefore indicate that the strongest
binding force betweenMCT andMPL® is not electrostatic, hydrophobic
or ligand exchange. The presence of grass allergoid in the MATA test
formulation did not signiﬁcantly reduce the level or speed of MPL®
adsorption.Fig. 2. Possible C–H⋯π interactions between the 2-deoxy-2-amMPL® content results for both Grass MATA and MCT formulations
containing 100 μg/mLMPL®after the addition of a naphthalene solution
at a 1:1 v/v ratiowere 27 and 8 μg/mLMPL® respectively, see Table 6 for
an overview of results at a 1:1 v/v ratio and Supplementary ﬁle 1 for ad-
ditional data. MPL® content results for supernatant samples of Grass
MATA and MCT formulations containing 100 μg/mL MPL® on addition
of naphthalene solution at a 1:1 v/v ratio were 73 and 92 μg/mL MPL®
respectively, see Table 6 for an overview of results at a 1:1 v/v ratio
and Supplementary ﬁle 1 for additional data.
The addition of a naphthalene solution to both GrassMATA andMCT
test formulations inhibited the adsorption of MPL® to suspended MCT
in the formulations. The structure of naphthalene consists only of two
aromatic rings, while the L-tyrosine in MCT contains one aromatic
ring, see Fig. 2. Results would therefore indicate that the strongest bind-
ing force between MCT and MPL® is based on an interaction between
the aromatic ring in MCT and MPL®, which the addition of an aqueous
naphthalene solution inhibited.
The presence of allergoid in the Grass MATA formulation reduced
the inhibition of adsorption of MPL® compared to MCT on the addition
of aqueous naphthalene. The grass allergoid present in the MATA com-
plex is likely to contain additional aromatic centres compared to MCT
alone, which could produce the reduced inhibition of naphthalene
seen in the Grass MATA test formulation.
4. Conclusion
The consistent adsorption of both allergoid andMPL® to theMCT in
MATA-MPL allergy immunotherapy formulations has been experimen-
tally proven and meets guideline recommendations. The type of
allergoid (tree, birch, grass and mugwort) or mix used in the MATA-
MPL allergy immunotherapy formulations does not affect its adsorption.
Competition binding experiments would indicate that the strongest
binding force is between the aromatic ring of L-tyrosine in MCT and
MPL®. The predisposition of MPL® to form aggregates in aqueous solu-
tions with outward facing phosphorylated 2-deoxy-2-aminoglucose
functional groups would support their involvement in any association,
as the hydrophobic fatty acid chains of MPL® are not exposed. Experi-
mentally the predominant adsorption forces do not appear to be elec-
trostatic or ligand exchange, suggesting that the phosphate group is
not predominantly involved. Therefore the association is likely to be
predominantly between the 2-deoxy-2-aminoglucose on MPL® and
the aromatic ring on L-tyrosine in MCT. The association could be basedinoglucose on MPL® and the aromatic ring on L-tyrosine.
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2-deoxy-2-aminoglucose backbone of MPL® and π electrons of the aro-
matic ring on L-tyrosine in MCT, commonly seen in carbohydrate–
protein interactions [48–50]. The possible C–H⋯π interaction between
MPL® and L-tyrosine is represented in Fig. 2. This type of association is
different from ligand exchange commonly seen between antigens and
aluminium adjuvants, which suggest that MCT could be an alternative
depot for infectious disease antigens that have proven difﬁcult to con-
sistently adsorb to aluminium adjuvants. Infectious disease antigens
such as anthrax, diphtheria and hepatitis B, where inconsistent or
poor antigen-adjuvant adsorption has been shown to affect potency
[2–8] could beneﬁt from formulation with MCT.
Additional biophysical techniques such as calorimetry, spectroscopy,
microscopy andNMR should be used to further characterise the interac-
tion ofMPL®and allergoids to L-tyrosine inMCT. Information describing
Langmuir coefﬁcients and kinetics would provide a good indication of
the strength of binding forces, so should also be investigated in further
work [8]. Immunological studies should be carried out to determine
the clinical beneﬁt of using MCT as an alternative depot for some infec-
tious disease antigens [55].
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